Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
Triple-negative breast cancer (TNBC) remains the most aggressive subtype of breast cancer. In the presence of distant metastases, the median overall survival does not exceed 14 months. TNBC is an extremely heterogeneous group of tumors, it includes both tumors extremely sensitive to chemotherapy and tumors that require targeted or immunotherapy for the best treatment outcomes. Such subtype features make it difficult to develop a single treatment strategy for all patients. Current perceptions of resistance mechanisms and molecular drivers progression have increased therapeutic opportunities for metastatic TNBC (mTNBC). For example, in the last few years, checkpoint inhibitors and PARP inhibitors have entered into clinical practice in the Russian Federation. This review presents clinical trial data, as well as an algorithm for choosing therapy for patients with TNBC, based on the results of recent clinical studies. The review focuses mainly on drugs registered at the territory of the Russian Federation, that allows to apply these options in everyday clinical practice. Promising directions therapy of mTNBC not registered at the territory of the Russian Federation yet will be showed in a separate review in the next issue in the Journal of Modern Oncology..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Современная онкология - 22(2021), 4, Seite 60-65 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Inna P. Ganshina [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Antiangiogenic therapy |
|---|
| doi: |
10.26442/18151434.2020.4.200495 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ067956718 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ067956718 | ||
| 003 | DE-627 | ||
| 005 | 20230309073104.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2021 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.26442/18151434.2020.4.200495 |2 doi | |
| 035 | |a (DE-627)DOAJ067956718 | ||
| 035 | |a (DE-599)DOAJa99aa8bbbad543218bc93d48c8adcbf6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a Inna P. Ganshina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel therapeutic strategies for patients with metastatic triple-negative breast cancer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Triple-negative breast cancer (TNBC) remains the most aggressive subtype of breast cancer. In the presence of distant metastases, the median overall survival does not exceed 14 months. TNBC is an extremely heterogeneous group of tumors, it includes both tumors extremely sensitive to chemotherapy and tumors that require targeted or immunotherapy for the best treatment outcomes. Such subtype features make it difficult to develop a single treatment strategy for all patients. Current perceptions of resistance mechanisms and molecular drivers progression have increased therapeutic opportunities for metastatic TNBC (mTNBC). For example, in the last few years, checkpoint inhibitors and PARP inhibitors have entered into clinical practice in the Russian Federation. This review presents clinical trial data, as well as an algorithm for choosing therapy for patients with TNBC, based on the results of recent clinical studies. The review focuses mainly on drugs registered at the territory of the Russian Federation, that allows to apply these options in everyday clinical practice. Promising directions therapy of mTNBC not registered at the territory of the Russian Federation yet will be showed in a separate review in the next issue in the Journal of Modern Oncology. | ||
| 650 | 4 | |a triple negative breast cancer | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a antiangiogenic therapy | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a parp inhibitors | |
| 650 | 4 | |a drug therapy | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 700 | 0 | |a Olga O. Gordeeva |e verfasserin |4 aut | |
| 700 | 0 | |a Mariam Sh. Manukian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Современная онкология |d IP Habib O.N., 2019 |g 22(2021), 4, Seite 60-65 |w (DE-627)DOAJ000110930 |x 18151442 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:4 |g pages:60-65 |
| 856 | 4 | 0 | |u https://doi.org/10.26442/18151434.2020.4.200495 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/a99aa8bbbad543218bc93d48c8adcbf6 |z kostenfrei |
| 856 | 4 | 0 | |u https://modernonco.orscience.ru/1815-1434/article/viewFile/61149/44238 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1815-1434 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1815-1442 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2021 |e 4 |h 60-65 | ||